Reaktionsgleichung
[Cl:1][C:2]1[C:3]([C:13]([F:16])([F:15])[F:14])=[N:4][NH:5][C:6]=1[C:7]1[CH:12]=[CH:11][CH:10]=[CH:9][CH:8]=1.C([O-])([O-])=O.[K+].[K+].Cl[CH2:24][C:25]([N:27]1[CH2:32][CH2:31][N:30]([C:33]2[CH:38]=[CH:37][C:36]([Br:39])=[C:35]([O:40][CH3:41])[CH:34]=2)[CH2:29][CH2:28]1)=[O:26].CN(C=O)C>CCCCCC.C(OCC)(=O)C>[Br:39][C:36]1[CH:37]=[CH:38][C:33]([N:30]2[CH2:31][CH2:32][N:27]([C:25](=[O:26])[CH2:24][N:4]3[C:3]([C:13]([F:14])([F:16])[F:15])=[C:2]([Cl:1])[C:6]([C:7]4[CH:12]=[CH:11][CH:10]=[CH:9][CH:8]=4)=[N:5]3)[CH2:28][CH2:29]2)=[CH:34][C:35]=1[O:40][CH3:41]Komponenten
6
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
Protocol T was followed using 4-Chloro-5-phenyl-3-trifluoromethyl-1H-pyrazole, K2CO3, 2-Chloro-1-[4-(4-bromo-3-methoxy-phenyl)-piperazin-1-yl]-ethanone and DMF. Column chromatography using a solvent mixture (hexane/ethyl acetate=2/3) afforded the title compound as a white solid. 1H NMR (400 MHz, CDCl3): 7.42–7.52 (m, 4H), 7.36–7.38 (d, 1H), 6.42–6.46 (d, 1H), 6.34–6.38 (dd, 1H), 4.72 (s, 2H), 3.88 (s, 3H), 3.74–3.78 (m, 2H), 3.54–3.58 (m, 2H), 3.12–3.18 (m, 4H). 13C NMR (400 MHz, CDCl3): 164, 156.2, 152, 132.6, 130.2, 130, 128.8, 110, 102.2, 56, 52, 50, 44.8, 42.
Quellen und Nachweise
- ORD-Eintrag
- ord-fe6225c9d92c4f13885d188adf49eb69
- Quelldatensatz
- uspto-grants-2007_01
- Patentnummer
- US07157464B2
Verknüpfte Notizen
Wird geladen…